WINTON GROUP Ltd Has $3.14 Million Stake in Hologic, Inc. (NASDAQ:HOLX)

WINTON GROUP Ltd lessened its position in Hologic, Inc. (NASDAQ:HOLX) by 38.6% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 43,526 shares of the medical equipment provider’s stock after selling 27,382 shares during the quarter. WINTON GROUP Ltd’s holdings in Hologic were worth $3,138,000 at the end of the most recent quarter.

A number of other institutional investors have also made changes to their positions in HOLX. Cerity Partners LLC boosted its stake in Hologic by 50.6% in the 3rd quarter. Cerity Partners LLC now owns 59,884 shares of the medical equipment provider’s stock valued at $4,878,000 after buying an additional 20,132 shares in the last quarter. Loomis Sayles & Co. L P grew its position in shares of Hologic by 29.3% during the 3rd quarter. Loomis Sayles & Co. L P now owns 808 shares of the medical equipment provider’s stock worth $66,000 after buying an additional 183 shares during the period. Private Trust Co. NA raised its position in shares of Hologic by 19.6% during the 3rd quarter. Private Trust Co. NA now owns 1,166 shares of the medical equipment provider’s stock valued at $95,000 after acquiring an additional 191 shares during the last quarter. Bank of Montreal Can lifted its stake in Hologic by 3.9% in the third quarter. Bank of Montreal Can now owns 492,210 shares of the medical equipment provider’s stock valued at $39,780,000 after buying an additional 18,532 shares during the period. Finally, Dai ichi Life Insurance Company Ltd acquired a new stake in shares of Hologic in the 3rd quarter valued at approximately $757,000. 94.73% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

HOLX has been the subject of several research analyst reports. Argus lowered Hologic from a “buy” rating to a “hold” rating in a research report on Monday, March 3rd. Stephens reiterated an “overweight” rating and set a $84.00 price objective on shares of Hologic in a report on Thursday, February 6th. Wolfe Research began coverage on Hologic in a research note on Friday, December 13th. They issued a “peer perform” rating on the stock. Jefferies Financial Group began coverage on shares of Hologic in a research note on Tuesday, December 10th. They set a “hold” rating and a $85.00 price target for the company. Finally, Citigroup cut their price objective on shares of Hologic from $80.00 to $70.00 and set a “neutral” rating on the stock in a research report on Tuesday, March 4th. Eleven analysts have rated the stock with a hold rating, six have given a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat.com, the company has an average rating of “Hold” and a consensus price target of $84.62.

Hologic Stock Performance

Shares of Hologic stock opened at $62.32 on Friday. The company’s 50 day moving average price is $65.41 and its two-hundred day moving average price is $73.50. The firm has a market capitalization of $13.98 billion, a P/E ratio of 19.66, a P/E/G ratio of 2.14 and a beta of 0.97. Hologic, Inc. has a fifty-two week low of $60.34 and a fifty-two week high of $84.67. The company has a debt-to-equity ratio of 0.52, a current ratio of 3.49 and a quick ratio of 2.78.

Hologic (NASDAQ:HOLX) last released its quarterly earnings data on Wednesday, February 5th. The medical equipment provider reported $1.03 earnings per share for the quarter, beating the consensus estimate of $1.02 by $0.01. Hologic had a return on equity of 19.72% and a net margin of 18.42%. On average, equities analysts forecast that Hologic, Inc. will post 4.28 earnings per share for the current fiscal year.

Hologic Company Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.